Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: central nervous system therapeutics - ArmaGen

Next Previous
Drug Profile

Research programme: central nervous system therapeutics - ArmaGen

Alternative Names: AGT-120; AGT-185; AGT-3100; Rett fusion protein - ArmaGen; Rett syndrome therapeutic - ArmaGen

Latest Information Update: 23 Apr 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ArmaGen Technologies
  • Class Antibodies; Enzymes; Immunoglobulin fusion proteins
  • Mechanism of Action Acetylcholinesterase inhibitors; Protein replacements; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain disorders; Major depressive disorder; Poisoning; Rett syndrome; Spinal cord injuries

Most Recent Events

  • 21 Apr 2020 ArmaGen Technologies has been acquired by JCR Pharmaceuticals
  • 13 Sep 2019 Discontinued for Rett syndrome in USA (unspecified route) (ArmaGen pipeline, September 2019)
  • 10 Sep 2019 Discontinued - Preclinical for Brain disorders in USA (IV) (ArmaGen pipeline, September 2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top